

# Antifungal Susceptibility of Yeast and Mould Isolates: 2001 to 2015

## % susceptible or wild-type<sup>1,2,3</sup>

Department of Clinical Microbiology, Auckland City Hospital. Clinical Microbiologists can be contacted through Lablink on 09 3078995 or 0800 5227587

≥ 90% susceptible or wild-type; 
  70-89% susceptible or wild-type; 
  < 70% susceptible or wild-type; 
 R = Resistant; - = no MIC/ECV data available

Classification Number: LPMICMYCIN017 Date issued: April 2018	Fluconazole	Voriconazole	Posaconazole	Itraconazole	Amphotericin	Micafungin <sup>5</sup>
Species / Complex (n) <sup>4</sup>						
<i>Candida albicans</i> (1034)	<b>95</b>	<b>96</b>	97	98	100	<b>99</b>
<i>Candida glabrata</i> (448)	<b>89<sup>6</sup></b>	- <sup>7</sup>	81	94	100	<b>96</b>
<i>Candida parapsilosis</i> (422)	<b>85</b>	<b>98</b>	99	100	100	<b>98</b>
<i>Candida tropicalis</i> (89)	<b>80</b>	<b>66</b>	<b>35</b>	95	100	<b>100</b>
<i>Clavispora lusitaniae</i> (44) (formerly <i>Candida lusitaniae</i> )	<b>57</b>	88	85	100	100	100
<i>Meyerozyma guilliermondii</i> (49) (formerly <i>Candida guilliermondii</i> )	93	85	100	100	100	<b>100</b>
<i>Pichia kudriavzevii</i> (51) (formerly <i>Candida krusei</i> )	R	<b>92</b>	<b>2</b>	98	100	<b>100</b>
<i>Cryptococcus neoformans</i> <sup>8</sup> (88)	86	99	100	99	<b>68</b>	-
<i>Aspergillus flavus</i> (16)	-	100	100	100	100	<b>38<sup>9</sup></b>
<i>Aspergillus fumigatus</i> (140)	-	100	-	100	100	96 <sup>9</sup>
<i>Aspergillus terreus</i> (8)	-	100	100	100	100	<b>25<sup>9</sup></b>
<i>Aspergillus niger</i> (10)	-	100	100	100	100	100 <sup>9</sup>

**The treatment of invasive fungal infection requires expert advice from specialists experienced in this area.**

<sup>1</sup> Susceptibility results derived from local and referred clinical isolates from other New Zealand laboratories. Isolates recovered from wide range of clinical specimens.

<sup>2</sup> Susceptible category defined by breakpoint minimal inhibitory concentrations (MICs). A category that implies that such isolates are inhibited by the usual achievable concentration when the antifungal is used at the recommended dosage to treat the site of infection.

**Percent susceptible are in bold.**

<sup>3</sup> Wild-type isolates, defined by epidemiological cutoff values (ECVs), are isolates without acquired resistance mechanisms. For this table ECVs derived by the YeastOne Sensititre method are used to determine the % wild-type. % wild-type are unbolded.

<sup>4</sup> Number of isolates tested. Due to changes in the YeastOne Sensititre panel over time not all isolates have been tested against all antifungal agents.

<sup>5</sup> Micafungin susceptibility predicts susceptibility to caspofungin.

<sup>6</sup> % Susceptible-dose dependent; a category defined by a breakpoint MIC that implies susceptibility depending on the increased dose required to treat. It should be determined if fluconazole is the appropriate antifungal to use. Expert consultation on selecting the maximum dosage regimen is recommended.

<sup>7</sup> Current data insufficient to correlate MIC and clinical outcome.

<sup>8</sup> No YeastOne ECVs published, CLSI derived ECVs used.

<sup>9</sup> No YeastOne derived micafungin ECVs exist, CLSI derived caspofungin ECVs used.